Literature DB >> 33089755

The factors associated with distress a minimum of six months after BRCA1/2 confirmation: A systematic review.

Ellen Butler1, Sonya Collier2, David Hevey1.   

Abstract

PROBLEM IDENTIFICATION: Many BRCA1/2 carriers experience an increase in distress after diagnosis; however, there is a need to review the longer term psychological implications of genetic confirmation and the factors associated with persistent distress. LITERATURE SEARCH: This article systematically reviewed the literature in line with PRISMA guidelines on distress a minimum of six months after BRCA1/2 confirmation focusing on prevalence rates and factors associated with distress. DATA EVALUATION AND SYNTHESIS: Fifteen studies were identified for inclusion and a narrative synthesis was conducted. Distress was associated with a range of demographic, clinical and psychological factors. A consistent finding was that although most carriers experience a reduction in distress 6-12 months after BRCA1/2 confirmation, those who experience persistent distress are more likely to have had higher distress levels at time of genetic testing. Risk reducing surgery may also play a role in reducing distress.
CONCLUSION: The review highlights the importance of psychological assessment and the use of specific distress measures. Given the considerable challenges in synthesizing the data there is a need for further prospective studies of high methodological quality.

Entities:  

Keywords:  Anxiety; BRCA/12; depression; distress; genetic testing; long-term

Mesh:

Substances:

Year:  2020        PMID: 33089755     DOI: 10.1080/07347332.2020.1836109

Source DB:  PubMed          Journal:  J Psychosoc Oncol        ISSN: 0734-7332


  1 in total

1.  Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.

Authors:  Adi Pomerantz; Daliah Tsoref; Ahuva Grubstein; Sonya Wadhawker; Yael Rapson; Itay Gadiel; Hadar Goldvaser; Ilan Feldhamer; Ariel Hammerman; Tzipora Shochat; Eran Sharon; Inbal Kedar; Rinat Yerushalmi
Journal:  Breast Cancer Res Treat       Date:  2022-04-07       Impact factor: 4.624

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.